Titan puts Parkinson's disease implant trial on hold after FDA asks for more data

By Gareth Macdonald

- Last updated on GMT

iStock/Zerbor
iStock/Zerbor

Related tags Food and drug administration

Titan Pharmaceuticals has put plans for a trial of its candidate Parkinson’s disease implant ropinirole after the US FDA asked for additional information.

The US firm announced “initiation of the clinical trial” was on hold in an SEC filing​, explaining that move would allow it to submit request information to the US regulator.

Titan said: “The FDA indicated that it will require final release test data on the ropinirole implant and the applicator used to insert the implant before clearing the IND​.”

The FDA has also asked Titan to appoint a principal investigator for the study.

Titan said the final test data on the implant and applicator will be available in a few weeks, adding that it is in the process of selecting trial sites.

The implant is based on Titan’s proneura delivery platform, which is designed to deliver steady levels of the dopamine agonist ropinirole for periods of three to six months.

Related news

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Products

View more

Webinars